Pharmacodynamic effects of daclizumab in the intrathecal compartment

Abstract

ObjectiveIt was previously demonstrated that daclizumab therapy normalizes cellular cerebrospinal fluid (CSF) abnormalities typical of multiple sclerosis (MS) in the majority of treated patients. However, CSF cells represent only the mobile portion of intrathecal immune responses. Therefore, we asked whether daclizumab also reverses compartmentalized inflammation and if not, whether residual inflammation correlates with clinical response to the drug.MethodsForty MS patients treated with an intravenous or subcutaneous injection of daclizumab were followed for up to 16 years in two open‐label clinical trials. MRI contrast‐enhancing lesions (CELs), clinical scales, and CSF biomarkers quantified residual disease.ResultsRapid decreases in CELs, sustained throughout the observation period, were observed with daclizumab treatment. Daclizumab therapy induced modest but statistically significant (P < 0.0001) decreases in CSF levels of T‐cell activation marker CD27 and IgG index. Interleukin 2 (IL‐2) CSF levels increased from baseline levels during treatment, consistent with reduced IL‐2 consumption by T cells, as a consequence of daclizumab's saturation of high‐affinity IL‐2 receptors. CSF levels of IL‐12p40, chitinase‐3‐like protein‐1 (CHI3L1), chemokine C‐X‐C motif ligand 13, and neurofilament light chain (NFL) were also significantly reduced by daclizumab. Among them, inhibition of CHI3L1 correlated with inhibition of NFL and with lack of disease progression.InterpretationThese observations confirm daclizumab's direct pharmacodynamics effects on immune cells within central nervous system tissues and identify inhibition of CSF biomarkers of myeloid lineage as a stronger determinant of reduction in clinical MS activity than inhibition of biomarkers of adaptive immunity.

Glucose and pH Dual‐Responsive Nanogels for Efficient Protein Delivery

“…Now protein drugs play a vital role for treating a broad range of diseases, including cancer, metabolic disorders, and autoimmune diseases . Certain types of protein drugs like Atezolizumab, zinbryta, and cytochrome C have been approved by FDA for clinical use . Protein drugs have been widely applied in the treatment of various diseases attributed to their high specificity, great activity, and superior biocompatibility .…”

Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients

“…Our data indicates that DMF used as a first-line treatment has similar potential in reducing NFL levels in the blood and CSF compared with highly effective DMTs even though this cohort demonstrated mild disease burden prior to initiation of treatment. A few studies have already shown that natalizumab,8 9 22 24 34 fingolimod,10 11 15 28 cladribine35 daclizumab36 and alemtuzumab13 are able to reduce NFL levels in both the CSF and/or blood 8 10 11 13 15 34 35…”

The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis

“…After 4-12 months of fingolimod treatment, CHI3L1 levels decreased but did not reach those of healthy controls (79). Daclizumab given intravenously or subcutaneously to 40 RRMS patients, participating in two open-label studies, significantly reduced CSF CHI3L1 levels at long-term follow-up (100). Interestingly, mitoxantrone treatment of MS patients (n=22; 3 RRMS, 19 SPMS), reduced CHI3L1 conscentrations in CSF (97).…”